Stay updated on Switching to Cabotegravir and Rilpivirine: Clinical Trial
Sign up to get notified when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.

Latest updates to the Switching to Cabotegravir and Rilpivirine: Clinical Trial page
- Check4 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.3%
- Check11 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
- Check18 days agoChange DetectedThe study has added 113 locations across various countries, including new entries in Argentina, Canada, France, Germany, Italy, South Korea, Mexico, Russia, South Africa, Spain, and Sweden, while removing 115 locations from the previous list, indicating a significant update in the geographical scope of the study.SummaryDifference4%
- Check25 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check32 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant revision.SummaryDifference0.0%
- Check61 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.0%
Stay in the know with updates to Switching to Cabotegravir and Rilpivirine: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.